Skip to main content
Clinical Trials/EUCTR2013-002980-24-IT
EUCTR2013-002980-24-IT
Active, not recruiting
Not Applicable

Comparative study to evaluate the effect on platelet aggregation of two different doses (20 and 40 mg) of acetylsalicylic acid administered sublingually compared to the dose of 100 mg of acetylsalicylic acid orally in subjects at increased cardiovascular risk. Prospective, randomized, double-blind, parallel-group for a period of three months - ASA-001

IRCCS San Raffaele di Roma0 sites261 target enrollmentAugust 9, 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
IRCCS San Raffaele di Roma
Enrollment
261
Status
Active, not recruiting
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 9, 2013
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
IRCCS San Raffaele di Roma

Eligibility Criteria

Inclusion Criteria

  • men or women
  • age \> 18 years
  • moderate\-high cardiovascular risk, assessed by using the SCORE system (\=1% and \<10% for 10\-year risk of fatal CVD), according to the European Guidelines on cardiovascular disease prevention in clinical practice
  • written informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 130
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 131

Exclusion Criteria

  • Age \< 18 years
  • Positive pregnancy test (ßGCH) performed at the selection visit or results not available, women who are pregnant, women who are breast\-feeding, women of childbearing potential who are not using reliable methods available to avoid pregnancy
  • Patients at very high or low cardiovascular risk, having a calculated SCORE \=10%
  • History of atrial fibrillation or atrial flutter
  • Patient in treatment with indication to oral anticoagulants or other antithrombotic drugs
  • Patient with history of hypersensitivity or intolerance with acetylsalicylic acid or other non steroidal ant\-iinflammatory drugs (NSAIDs)
  • Patients with any history of hereditary angioedema hereditary, idiopathic or associated with acetylsalicylic acid
  • Patients with history of peptic ulcers or gastritis or history of gastrointestinal bleeding associated to acetylsalicylic acid or other non steroidal anti\-inflammatory drugs (NSAIDs)
  • Patients with severe gastro\-intestinal tract disorders
  • Patient with asthma or NSAID\-precipitated bronchospasm

Outcomes

Primary Outcomes

Not specified

Similar Trials